Dismal prognosis for cirrhotic patients with hepatitis C after initial failure of direct acting anti-virals, but salvage therapy may be life-saving

References

• Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am. 2015;44(4):717–734. doi: 10.1016/j.gtc.2015.07.003.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–369. doi: 10.1056/NEJMoa1702417.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13. doi: 10.7326/M15-0785.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–2607. doi: 10.1056/NEJMoa1512610.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Carrion JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020;72(6):1112–1121. doi: 10.1016/j.jhep.2020.01.025.
   PubMed Web of Science ®Google Scholar
• Berg T, Naumann U, Stoehr A, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the german hepatitis C-Registry. Aliment Pharmacol Ther. 2019;49(8):1052–1059. doi: 10.1111/apt.15222.
   PubMed Web of Science ®Google Scholar
• Mangia A, Milligan S, Khalili M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts. Liver Int. 2020;40(8):1841–1852. doi: 10.1111/liv.14537.
   PubMed Web of Science ®Google Scholar
• Sweden Statistics. Mortality rate, per 1,000 of the mean population by age, sex and year. 2022. Available from: https://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101I/Dodstal/table/tableViewLayout1/.
   Google Scholar
• Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–2146. doi: 10.1056/NEJMoa1613512.
   PubMed Web of Science ®Google Scholar
• Xie J, Xu B, Wei L, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: a systematic review and meta-analysis. Infect Dis Ther. 2022;11(4):1661–1682. doi: 10.1007/s40121-022-00666-0.
   PubMed Web of Science ®Google Scholar
• Degasperi E, Spinetti A, Lombardi A, et al. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019;71(6):1106–1115. doi: 10.1016/j.jhep.2019.07.020.
   PubMed Web of Science ®Google Scholar
• Llaneras J, Riveiro-Barciela M, Lens S, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol. 2019;71(4):666–672. doi: 10.1016/j.jhep.2019.06.002.
   PubMed Web of Science ®Google Scholar
• Wilson E, Covert E, Hoffmann J, et al. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). J Hepatol. 2019;71(3):498–504. doi: 10.1016/j.jhep.2019.05.021.
   PubMed Web of Science ®Google Scholar
• European association for the study of the liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170–1218.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Morgan TR; Panel Aasld-Idsa Hepatitis C Guidance. Hepatitis C guidance 2019 update: american association for the study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721. doi: 10.1002/hep.31060.
   PubMed Web of Science ®Google Scholar
• Patel S, Martin MT, Flamm SL. Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis. Liver Int. 2021;41(12):3024–3027. doi: 10.1111/liv.15075.
   PubMed Web of Science ®Google Scholar
• Hanafy AS, Soliman S, Abd-Elsalam S. Rescue therapy for chronic hepatitis C virus infection after repeated treatment failures: impact on disease progression and risk of hepatocellular carcinoma. Hepatol Res. 2019;49(4):377–384. doi: 10.1111/hepr.13303.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Cooper CL, Manns MP, et al. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. J Hepatol. 2018;69(6):1221–1230. doi: 10.1016/j.jhep.2018.07.023.
   PubMed Web of Science ®Google Scholar
• Lagging M, Wejstal R, Duberg AS, et al. Treatment of hepatitis C virus infection for adults and children: updated swedish consensus guidelines 2017. Infect Dis (Lond). 2018;50(8):569–583. doi: 10.1080/23744235.2018.1445281.
   PubMed Web of Science ®Google Scholar
• Backus LI, Belperio PS, Shahoumian TA, et al. Impact of sustained virologic response with Direct-Acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology. 2019;69(2):487–497. doi: 10.1002/hep.29408.
   PubMed Web of Science ®Google Scholar
• Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453–1464. doi: 10.1016/S0140-6736(18)32111-1.
   PubMed Web of Science ®Google Scholar
• Mendizabal M, Pinero F, Ridruejo E, et al. Disease progression in patients With hepatitis C virus infection treated With Direct-Acting antiviral agents. Clin Gastroenterol Hepatol. 2020;18(11):2554–2563 e3. doi: 10.1016/j.cgh.2020.02.044.
   PubMed Web of Science ®Google Scholar
• Krassenburg LAP, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021;74(5):1053–1063. doi: 10.1016/j.jhep.2020.11.021.
   PubMed Web of Science ®Google Scholar
• Kushner T, Dieterich D, Saberi B. Direct-acting antiviral treatment for patients with hepatocellular carcinoma. Curr Opin Gastroenterol. 2018;34(3):132–139. doi: 10.1097/MOG.0000000000000431.
   PubMed Web of Science ®Google Scholar